Activation of gp120 of human immunodeficiency virus by their V3 loop-derived peptides

Biochemical and Biophysical Research Communications

Volumn 297, Issue 3, 2002, Pages 625-631

  Ling, Hong ^a   Zhang, Xiao Yan ^a   Usami, Osamu ^a   Hattori, Toshio ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Entry; Envelope; gp120; Human immunodeficiency virus type 1 (HIV 1); Retrovirus; Synthetic peptide; V3 loop

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; EPITOPE; GLYCOPROTEIN GP 120; LUCIFERASE; PEPTIDE DERIVATIVE; VIRUS PROTEIN;

ARTICLE; BINDING SITE; CONTROLLED STUDY; ENVELOPE GENE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REPORTER GENE; TARGET CELL; VIRUS ACTIVATION; VIRUS ENVELOPE; VIRUS INFECTIVITY; VIRUS STRAIN;

ANTIBODIES, MONOCLONAL; CELL LINE; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; KIDNEY; PEPTIDE FRAGMENTS; PLASMIDS; RECOMBINANT PROTEINS; TRANSFECTION;

ADA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; UNIDENTIFIED RETROVIRUS;

EID: 0036387173     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(02)02253-2     Document Type: Article

References (36)

1. R. Wyatt, J. Sodroski, The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens, Science 19 (1998) 1884-1888.
2. J.P. Moore, J.A. Mckeating, W.A. Norton, Q.J. Sattentau, Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4, J. Virol. 65 (1991) 1133-1140.
3. S.B. Jiang, K. Lin, A.R. Neurath, Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41, J. Exp. Med. 175 (1991) 1557-1563.
4. J.S. Allan, Receptor-mediated activation of immunodeficiency viruses in viral fusion, Science 252 (1991) 1322-1323.
5. J.P. Moore, Y. Cao, L. Qing, Q.J. Sattentau, J. Pyati, R. Koduri, J. Robinson, C.F. Barbas III, D.R. Burton, D.D. Ho, Primary isolates of human immunodeficiency virus type1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120, J. Virol. 69 (1995) 101-109.
6. N. Sullivan, Y. Sun, J. Binley, J. Lee, C.F. Barbas, P.W.H.I. Parren, D.R. Burton, J. Sodroski, Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies, J. Virol. 72 (1998) 6332-6338.
7. S. Matsushita, M.R. Guroff, J. Rusche, T. Hattori, H. Hoshino, K. Javaherian, K. Takatsuki, S. Putney, Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope, J. Virol. 62 (1988) 2107-2114.
8. T. Shioda, J.A. Levy, C. Cheng-Mayer, Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1, Nature 10 (1991) 167-169.
9. T. Murakami, T. Hattori, K. Takatsuki, A principal neutralizing domain of human immunodeficiency virus type 1 interacts with proteinase-like molecule(s) at the surface of Molt-4 clone 8 cells, Biochim. Biophys. Acta 1079 (1991) 279-284.
10. H. Sakaida, T. Hori, A. Yonezawa, A. Sato, Y. Isaka, O. Yoshie, T. Hattori, T. Uchiyama, T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection, J. Virol. 72 (1998) 9763-9770.
11. A. Koito, T. Hattori, T. Murakami, S. Matsushita, Y. Maeda, T. Yamamoto, K. Takatsuki, A neutralizing epitope of human immunodeficiency virus type 1 has homologous amino acid sequences with the active site of inter-α-trypsin inhibitor, Int. Immunol. 1 (1989) 613-618.
12. P.N. Nehete, R.B. Arlinghaus, J. Sastry, Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120, J. Virol. 67(1993) 6841-6846.
13. A.D. Rossi, M. Pasti, F. Mammano, M. Panozzo, M. Dettin, C.D. Bello, L.C. Bianchi, Synthetic peptides from the principal neutralizing domain of human immunodeficiency virus type 1 (HIV-1) enhance HIV-1 infection through a CD4-dependent mechanism, Virology 184 (1991) 187-196.
14. M. Dettin, C. Scarinci, C. Zanotto, R. Roncon, A.D. Rossi, C.D. Bello, Biological and conformational studies on analogues of a synthetic peptide enhancing HIV-1 infection, J. Pept. Sci. 4 (1998) 436-448.
15. H. Sakaida, T. Murakami, S. Kawamata, T. Hattori, T. Uchiyama, V3 loop of human immunodeficiency virus type 1 suppresses interlukin 2-induced T cell growth, AIDS Res. Hum. Retroviruses 13(1997) 151-159.
16. R.I. Connor, B.K. Chen, S. Choe, N.R. Landau, Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes, Virology 206 (1995) 935-944.
17. H. Deng, R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P.D. Marzio, S. Marmon, R.E. Sutton, C.M. Hill, C.B. Davis, S.C. Peiper, T.J. Schall, D.R. Littman, N.R. Landau, Identification of a major co-receptor for primary isolates of HIV-1, Nature 381 (1996) 661-666.
18. W.S. Pear, G.P. Nolan, M.L. Scott, D. Baltimore, Production of high-titer helper-free retroviruses by transient transfection, Proc. Natl. Acad. Sci. USA 90 (1993) 8392-8396.
19. J. Kimpton, M. Emerman, Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene, J. Virol. 66 (1992) 2232-2239.
20. C.D. Weiss, J.M. White, Characterization of stable Chinese hamster ovary cells expressing wild-type, secreted, and glycosylphosphatidylinositol-anchored human immunodeficiency virus type 1 envelope glycoprotein, J. Virol. 67 (1993) 7060-7066.
21. N.R. Landau, K.A. Page, D.R. Littman, Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range, J. Virol. 65 (1991) 162-169.
22. S.L. Li, X.Y. Zhang, H. Ling, T. Hattori, A VSV-G pseudotyped HIV vector mediates efficient transduction of human pulmonary artery smooth muscle cells, Microbiol. Immunol. 44 (2000) 1019-1025.
23. M.D. Eckert, V.N. Malashkevich, L.H. Hong, P.A. Carr, P.S. Kim, Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket, Cell 99 (1999) 103-115.
24. M.J. Endres, P.R. Clapham, M. Marsh, M. Ahuja, J.D. Turner, J. McKnight, J.F. Thomas, B. Stoebenau-Haggarty, S. Choe, P.J. Vance, T.N. Wells, C.A. Power, S.S. Sutterwala, R.W. Doms, N.R. Landau, J.A. Hoxie, CD4-independent infection by HIV-2 is mediated by fusin/CXCR4, Cell 87 (1996) 745-756.
25. L. Wu, G. LaRosa, N. Kassam, C.J. Gordon, H. Heath, N. Ruffing, H. Chen, J. Humblias, M. Samson, M. Parmentier, J.P. Moore, C.R. Mackay, Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding, J. Exp. Med. 186 (1997) 1373-1381.
26. M.R. Posner, T. Hideshima, T. Cannon, M. Mukherjee, K.H. Mayer, R.A. Byrn, An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection, J. Immunol. 146 (1991) 4325-4332.
27. D.R. Burton, J. Pyati, R. Koduri, S.J. Sharp, G.B. Thornton, P.W. Parren, L.S.W. Sawyer, R.M. Hendry, N. Dunlop, P.L. Nara, M. Lamacchia, E. Garratty, E.R. Stiehm, Y.J. Bryson, Y. Cao, J.P. Moore, D.D. Ho, C.F. Barbas III, Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody, Science 266 (1994) 1024-1027.
28. L. Wu, N.P. Gerard, R. Wyatt, H. Choe, C. Parolin, N. Ruffing, A. Borsetti, A.A. Cardoso, E. Desjardin, W. Newman, C. Gerard, J. Sodroski, CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5, Nature 384 (1996) 179-183.
29. C.D. Rizzuto, R. Wyatt, N. Hernandez-Ramos, Y. Sun, P.D. Kwong, W.A. Hendrickson, J. Sodroski, A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding, Science 280 (1998) 1949-1953.
30. N. Sullivan, Y. Sun, Q. Sattentau, M. Thali, D. Wu, G. Denisova, J. Gershoni, J. Robinson, J. Moore, J. Sodroski, CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization, J. Virol. 72 (1998) 4694-4703.
31. P.N. Nyambi, M.K. Gorny, L. Bastiani, G. van der Groen, C. Williams, S. Zolla-Pazner, Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1, J. Virol. 72 (1998) 9384-9391.
32. C. Guillon, M. Schutten, P.H.M. Boers, R.A. Gruters, Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction, J. Virol. 76 (2002) 2728-2834.
33. A. Koito, L. Stamatatos, C. Cheng-Mayer, Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120, Virology 206 (1995) 878-884.
34. M.K. Lee, M.A. Martin, M.W. Cho, Higher western blot immunoreactivity of glycoprotein 120 from R5 HIV type 1 isolates compared with X4 and X4R5 isolates, AIDS Res. Hum. Retroviruses 16 (2000) 765-775.
35. H.X. Liao, B. Etemad-Moghadam, D.C. Montefiori, Y. Sun, J. Sodroski, R.M. Scearce, R.W. Doms, J.R. Thomasch, S. Robinson, N.L. Letvin, B.F. Haynes, Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains, J. Virol. 74 (2000) 254-263.
36. C.B. Zhu, L. Zhu, S. Holz-Smith, T.J. Matthews, C.H. Chen, The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012, Proc. Natl. Acad. Sci. USA 98 (2001) 15227-15232.